600201.SH
生物股份
SSE · Healthcare · Biotechnology · CN
CNY 12.43
−1.74%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.4B | 1.3B | 1.6B | 1.5B |
| Cost of Revenue | 650.2M | 648.9M | 579.3M | 655.5M | 685.3M |
| Gross Profit | 741.1M | 747.5M | 676.1M | 942.7M | 843.4M |
| Operating Expenses | |||||
| R&D Expense | 112.0M | 131.1M | 136.8M | 143.5M | 133.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 187.3M | 189.6M | 143.1M | 152.6M | 127.4M |
| Selling & Marketing Expense | 336.7M | 335.4M | 289.2M | 339.0M | 294.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 614.2M | 629.4M | 541.3M | 602.0M | 531.8M |
| Cost and Expenses | 1.3B | 1.3B | 1.1B | 1.3B | 1.2B |
| Operating Income (EBIT) | 106.2M | 104.8M | 124.7M | 315.2M | 255.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 105.3M | 104.6M | 124.9M | 315.8M | 245.6M |
| Income Tax Expense | 5.3M | 9.1M | 20.8M | 38.7M | 45.5M |
| Bottom Line | |||||
| Net Income | 104.3M | 100.1M | 109.0M | 283.6M | 210.7M |
| Earnings from Cont. Ops | 100.0M | 95.5M | 104.2M | 277.1M | 200.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 104.3M | 100.1M | 109.0M | 283.6M | 210.7M |
| Per Share | |||||
| Basic EPS | CN¥0.09 | CN¥0.09 | CN¥0.10 | CN¥0.26 | CN¥0.19 |
| Diluted EPS | CN¥0.09 | — | — | — | — |
| Revenue Per Share | CN¥1.21 | CN¥1.26 | CN¥1.15 | CN¥1.47 | CN¥1.38 |
| Shares | |||||
| Basic Shares Outstanding | 1.2B | 1.1B | 1.1B | 1.1B | 1.1B |
| Diluted Shares Outstanding | 1.2B | 1.1B | 1.1B | 1.1B | 1.1B |
| Profitability Metrics | |||||
| EBITDA | — | 363.6M | 341.2M | 503.9M | 454.3M |
| D&A | — | 258.8M | 216.5M | 188.7M | 199.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026